Insmed, Inc. (NASDAQ:INSM) is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, INSM is expected to report 3Q20 loss of $ 0.61 per share from revenue of $ 46.07 million.
For the full year, analysts anticipate top line of $ 173.46 million, while looking forward to loss of $ 2.63 per share bottom line.
Previous Quarter Performance
Insmed, Inc. recorded loss for the second quarter of $ 0.64 per share, from the revenue of $ 42.49 million. The quarterly revenues raised 41.78 percent compared with the same quarter last year. Street analysts expected Insmed, Inc. to report loss of $ 0.63 per share on revenue of $ 34.51 million for the second quarter. The bottom line results missed street analysts by $ 0.01 or 1.59 percent, at the same time, top line results outshined analysts by $ 7.98 million or 23.12 percent.
Stock Performance
Shares of Insmed, Inc. traded low $ -1.03 or -2.83 percent on Wednesday, reaching $ 35.20 with volume of 674.50 thousand shares. Insmed, Inc. has traded high as $ 36.06 and has cracked $ 34.39 on the downward trend
According to the previous trading day, closing price of $ 35.20, representing a 199.59 % increase from the 52 week low of $ 12.09 and a 8.05 % decrease over the 52 week high of $ 39.39.
The company has a market capital of $ 3.57 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Insmed, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.insmed.com
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
